• Targeted and controlled. TheraPEG ™ technology has been designed to be specific for accessible cysteine residues occurring naturally within proteins. It allows PEG to be attached as well as overall protein structure, fold and function to be maintained - with minimal loss of bioactivity.

• Versatile. Chemistry can be conducted over a wide pH range; unconjugated protein can be recovered and used in further rounds of PEGylation. Increased solubility and stabilisation of conjugated product is also achievable.

• Efficient. TheraPEG ™ technology is a rapid process, conducted at a high conversion rate with low stoichiometry of reagent. Generates conjugated products that are purified in a simple, straightforward manner. High quality active product is readily achievable in high yield.

• Cost effective. Increased PEGylation efficiencies achievable with TheraPEG ™ technology allow improved yields of homogeneous product of predictable potency to be generated.

• Easily scaled up. Whereas some exiting technologies suffer from variation in PEGylation upon scale up, TheraPEG ™ technology is scale-independent.

Furthermore, at earlier stages in the drug discovery process, preclinical validation of protein-based leads becomes more efficient using TheraPEG ™ technology, since it overcomes their rapid in vivo clearance in disease-relevant pharmacological models.